| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443865 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
The results are considered as inconclusive since neither inferiority nor non-inferiority of treatment with neratinib versus lapatinib plus capecitabine could be demonstrated. The study confirmed relevant single-agent clinical activity and acceptable overall tolerability of neratinib in patients with recurrent HER2+ advanced breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Miguel Martin, Jacques Bonneterre, Charles E. Jr., Yoshinori Ito, Jungsil Ro, Istvan Lang, Sung-Bae Kim, Caroline Germa, Jennifer Vermette, Kenneth Wang, Kongming Wang, Ahmad Awada,